Oxeia Biopharma in the News
News Release: Oxeia Biopharmaceuticals Announces Clinical Advancement of Concussion Treatment
Oxeia Biopharmaceuticals Inc., announces its acquisition of the license to SUN11031, synthetic human ghrelin, from Kinemed Inc. Oxeia will develop SUN11031 as OXE103 to treat concussions and other acute neurotrauma.
News Release: Christopher Nowinski Joins Oxeia
Christopher Nowinski, co-founder and CEO of the Concussion Legacy Foundation, has joined the company’s Advisory Board.
News Release: Oxeia Biopharma Advancing Treatment of Concussions
Oxeia Biopharmaceuticals, Inc. Advancing Development of OXE103 for the Treatment of Concussions
“I became an advisor to Oxeia to contribute to an action that could change the face of how concussions are treated. Wouldn’t it be great if football players, hockey players and boxers, among others, could play their sport without the constant worry of repercussions from getting walloped in the head? Oxeia’s progress toward the delivery of a treatment for concussions fills me with great excitement about the future of sports.”
Richard Sherman
Cornerback for the San Francisco 49ers and
Advisory Board Member, Oxeia Biopharmaceuticals